BIT:DIA - Euronext Milan - IT0003492391 - Common Stock - Currency: EUR
BIT:DIA (6/6/2025, 12:55:11 PM)
91.51
+0.45 (+0.49%)
The current stock price of DIA.MI is 91.51 EUR. In the past month the price decreased by -5.93%. In the past year, price decreased by -10.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABL.DE | ABBOTT LABORATORIES | 27.8 | 202.17B | ||
IUI1.DE | INTUITIVE SURGICAL INC | 73.57 | 176.40B | ||
1ISRG.MI | INTUITIVE SURGICAL INC | 73.13 | 175.36B | ||
1BSX.MI | BOSTON SCIENTIFIC CORP | 42.18 | 136.95B | ||
BSX.DE | BOSTON SCIENTIFIC CORP | 38.14 | 133.15B | ||
1SYK.MI | STRYKER CORP | 31.59 | 128.51B | ||
2M6.DE | MEDTRONIC PLC | 15.83 | 97.67B | ||
1SHL.MI | SIEMENS HEALTHINEERS AG | 20.92 | 53.08B | ||
SHL.DE | SIEMENS HEALTHINEERS AG | 20.46 | 52.17B | ||
BOX.DE | BECTON DICKINSON AND CO | 12.22 | 43.18B | ||
EWL.DE | EDWARDS LIFESCIENCES CORP | 29.86 | 39.94B | ||
DC4.DE | DEXCOM INC | 51.98 | 29.35B |
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,271 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
DIASORIN SPA
Via Crescentino Snc
Saluggia VERCELLI IT
Employees: 3271
Phone: 3901614871
The current stock price of DIA.MI is 91.51 EUR. The price increased by 0.49% in the last trading session.
The exchange symbol of DIASORIN SPA is DIA and it is listed on the Euronext Milan exchange.
DIA.MI stock is listed on the Euronext Milan exchange.
19 analysts have analysed DIA.MI and the average price target is 110.64 EUR. This implies a price increase of 20.9% is expected in the next year compared to the current price of 91.51. Check the DIASORIN SPA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DIASORIN SPA (DIA.MI) has a market capitalization of 5.12B EUR. This makes DIA.MI a Mid Cap stock.
DIASORIN SPA (DIA.MI) currently has 3271 employees.
DIASORIN SPA (DIA.MI) has a support level at 90.93 and a resistance level at 96.68. Check the full technical report for a detailed analysis of DIA.MI support and resistance levels.
The Revenue of DIASORIN SPA (DIA.MI) is expected to grow by 5.65% in the next year. Check the estimates tab for more information on the DIA.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DIASORIN SPA (DIA.MI) has a dividend yield of 1.32%. The yearly dividend amount is currently 1.14. Check the full fundamental report for a detailed analysis of DIA.MI dividend history, reliability and sustainability.
DIASORIN SPA (DIA.MI) will report earnings on 2025-07-28.
The PE ratio for DIASORIN SPA (DIA.MI) is 26. This is based on the reported non-GAAP earnings per share of 3.52 and the current share price of 91.51 EUR. Check the full fundamental report for a full analysis of the valuation metrics for DIA.MI.
ChartMill assigns a fundamental rating of 6 / 10 to DIA.MI. DIA.MI has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months DIA.MI reported a non-GAAP Earnings per Share(EPS) of 3.52. The EPS increased by 16.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 15.87% | ||
ROA | 5.69% | ||
ROE | 10.44% | ||
Debt/Equity | 0.54 |
ChartMill assigns a Buy % Consensus number of 72% to DIA.MI. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 22.21% and a revenue growth 5.65% for DIA.MI